Alexion dumps ex-Achillion C3G program after seeing phase 2 data

Alexion has scrapped development of the lead asset acquired in its $930 million takeover of Achillion Pharmaceuticals in one indication. The action follows a “suboptimal” clinical response in two phase 2 trials in C3 glomerulopathy (C3G) patients that were expected to support global regulatory talks.